News

Hillary talks healthcare policy

BY Michael Johnsen

Former secretary of state Hillary Clinton joined attendees for day two of the NACDS Total Store Expo Monday morning to discuss her experiences as secretary of state, leading diplomatic talks on a variety of foreign policy, and she spoke extensively about her work on health reform.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medicare Part D, the Affordable Care Act and a steady stream of baby boomers qualifying for Medicare are all trends driving more patients to the pharmacy counter. And it’s not just prescriptions they’ll be picking up. “I personally love that more drug stores are offering healthier foods and [fitness items],” Clinton said.

On message with the industry’s “Pharmacy: The face of neighborhood health care,” Clinton noted the important role pharmacy can play to increase access to health care. “Each of you has a chance to help us find the answers and exercise leadership,” she said.

During a question-and-answer session with NACDS president and CEO Steve Anderson, Clinton spoke to her efforts at healthcare reform 20 years ago during the Bill Clinton presidency. However, in that time frame healthcare costs continued to skyrocket with outcomes not commensurate with the healthcare investment made. “We don’t have enough transparency in cost,” she said.

“It’s very difficult to get cost down in a system that doesn’t coordinate care and doesn’t cover every American,” she added.

“We have a chance to really see what we can learn,” Clinton said regarding the present-day healthcare reform. “We’re on a learning curve here. That’s why what the members of the association are doing are so important.”

“I’m here today in part to thank you — America’s pharmacists and drug store [operators] are still on the front lines of healthcare delivery,” she said.

“If we follow the example of many of you … we will make progress [in realizing healthcare reform],” she added. “It is no surprise that year after year that Americans rank pharmacists among the most-trusted professionals in the country.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Moberg Pharma’s Kerasal NeuroCream launches at U.S. drug stores, Walmart

BY Jason Owen

STOCKHOLM, Sweden — Moberg Pharma AB today announced its U.S. launch of Kerasal NeuroCream, an over-the-counter pain relieving foot cream. This new product will be sold in over 3,800 Walmart stores and in CVS, Walgreens, and Rite Aid drug stores starting late August.

Approximately 30 million Americans experience frequent foot pain and many simultaneously suffer from cold feet and dry skin. Painful, cold, dry feet may be associated with various conditions, including diabetes, fibromyalgia, shingles, arthritis, joint pain, muscle strain, or trauma. Kerasal NeuroCream is a triple action formula that relieves stabbing, burning, tingling foot pain, warms cold feet, and soothes and moisturizes dry skin. Kerasal NeuroCream is easily applied with a “no mess” foam applicator.

The active ingredients of Kerasal NeuroCream, capsaicin and camphor, have a well-established use as topical pain relievers, are naturally occurring and derived from plants. Moberg Pharma has utilized its Fusome skin delivery system, currently used in Moberg’s JointFlex Pain Relieving Cream, to formulate Kerasal NeuroCream, enabling a rapid delivery of effective pain relievers to the pain source.

“Kerasal NeuroCream is an innovative addition to our product portfolio. It leverages one of our existing drug delivery technologies along with proven active ingredients, to provide a solution that meets an unmet consumer need. Kerasal NeuroCream further strengthens the Kerasal brand, our leadership in the topical OTC foot care space in the U.S. and our value to retail partners”, said Peter Wolpert, CEO of Moberg Pharma AB.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Derma Sciences launches first honey-based OTC product to retail shelves

BY Jason Owen

PRINCETON, N.J. — Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that it has made an initial shipment of its first honey-based over-the-counter product to a leading U.S.-based pharmacy chain. This private-label dressing is based on the Medihoney HCS dressing, which is an ideal dressing for dry to lightly exuding wounds including minor burns, cuts and abrasions. The dressing is expected to be on the shelves in more than 4,000 stores by the end of September. This OTC dressing is expected to add approximately $1.2 million to Derma Sciences’ traditional wound care sales in the second half of 2013.

“The development of an OTC honey-based dressing is an important achievement for Derma Sciences and is indicative of our ability to modify our advanced wound care products to the consumer market,” said Edward J. Quilty, Derma Sciences chairman and chief executive officer. “We are thrilled that this large pharmacy chain has recognized the quality of our products and are excited to offer this innovative dressing, our first honey-based OTC dressing, to the broader market.”

As part of the private-label supply agreement, Derma Sciences will be working with the pharmacy chain to encourage adoption and utilization. The company will launch a similar dressing into the professional market during the fourth quarter in order to create initial awareness and demand within the hospital setting, and then educate patients and caregivers to the product’s availability within the retail pharmacy setting.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?